OBHSA（Oxabicycloheptane sulfonamide） is a novel selective estrogen receptor depressant (SERD) that can be used to study breast cancer.

Serdemetan (JNJ-26854165) is an orally bioavailable HDM2 antagonist with potential antineoplastic activity.

GLL 398 is an orally active and selective degrader of estrogen receptor with an IC50 of 1.14 nM. GLL 398 blocks tumor growth in xenograft breast cancer models.

GW5638 is a estrogen receptor ligand. GW5638 is a prodrug of its active metabolite GW7604. GW5638 appears to act as an antagonist in these in vitro systems, although in a manner distinct from other known ER modulators. GW5638 is also classified as a pseud

Imlunestrant tosylate (LY-3484356) is a potent, orally active selective estrogen receptor degrader (SERD) exhibiting purely antagonistic properties. It effectively maintains inhibition of estrogen receptor (ER)-dependent gene transcription and inhibits cell growth. This compound is applicable in research on ER-positive (ER+) advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC) [1] [2].

Elacestrant (RAD1901) with IC50s of 48 and 870 nM for ERα and ERβ, respectively.Elacestrant  is an orally available selective estrogen receptor degrader .

Elacestrant dihydrochloride (DA-DKRAD1901 dihydrochloride) is an orally available selective estrogen receptor degrader with IC50s of 48 for ERα and 870 nM for ERβ, respectively.

GNE-149 is an orally bioavailable compound that acts as a full antagonist of estrogen receptor α (ERα) with an IC50 of 0.053 nM. It is also classified as a selective estrogen receptor degrader (SERD). GNE-149 holds potential for research in the field of breast cancer.

ERα degrader-2 is a selective and potent estrogen receptor (SERD) degrader with anticancer activity, inhibits ERα, and has an EC50 value for estrogen receptor degradation of 0.3 nM.ERα degrader-2 can be used for the prevention and treatment of HER-positive breast cancer.

Imlunestrant is a selective, orally active estrogen receptor degrader (SERD) that can be used in ER+ and HER2 breast cancer studies.

AZD9496 maleate is a highly potent and selective antagonist of the estrogen receptor alpha (ERα), exhibiting an IC50 value of 0.28 nM. This compound, AZD9496 maleate, is an orally bioavailable selective estrogen receptor degrader (SERD).

Amcenestrant (SAR439859) is an orally active, nonsteroidal and selective degrader of estrogen receptor (SERD). SAR439859 is a potent antagonist of ER (with an EC50 of 0.2 nM for ERα degradation).

Rintodestrant (G1T48) is an orally active, non-steroidal, selective estrogen receptor degrader (SERD) that also functions as a CDK4/6 inhibitor.

THIQ-40 is a novel potent erα antagonist and selective estrogen receptor degrader (serd), exhibiting good oral bioavailability, antitumor efficacy, and serd activity in vivo

Taragarestrant (D-0502) meglumine is a potent, orally active, and selective estrogen receptor degrader (SERD) demonstrating significant efficacy in ER+ breast cancer cell lines and xenograft models [1] [2].